Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Cash Flow Reinvestment Rate
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Cash Flow Reinvestment Rate of 0.94x as of December 2025, reinvesting CN¥270.12 Million (capex CN¥20.11 Million plus investments CN¥250.02 Million) from operating cash flow of CN¥287.81 Million. Check 002393 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2007–2025)
Historical reinvestment intensity for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. Explore 002393 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Year-by-year capital reinvestment analysis for Tianjin Lisheng Pharmaceutical Co Ltd. For live market cap and broader valuation context, see 002393 market cap overview.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.36x | CN¥163.21 Million | CN¥451.85 Million | CN¥37.46 Million | ▼ -88.4% |
| 2024 | 3.13x | CN¥275.93 Million | CN¥88.26 Million | CN¥53.75 Million | ▲ +19.5% |
| 2023 | 2.62x | CN¥548.18 Million | CN¥209.51 Million | CN¥61.72 Million | ▲ +341.1% |
| 2022 | 0.59x | CN¥196.55 Million | CN¥331.38 Million | CN¥40.91 Million | ▼ -29.1% |
| 2021 | 0.84x | CN¥164.36 Million | CN¥196.34 Million | CN¥88.24 Million | ▼ -37.0% |
| 2020 | 1.33x | CN¥101.41 Million | CN¥76.37 Million | CN¥100.66 Million | ▲ +254.1% |
| 2019 | 0.37x | CN¥100.62 Million | CN¥268.33 Million | CN¥90.46 Million | ▼ -46.8% |
| 2018 | 0.70x | CN¥114.59 Million | CN¥162.69 Million | CN¥104.43 Million | ▲ +109.5% |
| 2017 | 0.34x | CN¥60.25 Million | CN¥179.25 Million | CN¥50.09 Million | ▼ -82.0% |
| 2016 | 1.86x | CN¥323.67 Million | CN¥173.60 Million | CN¥137.20 Million | ▲ +32.1% |
| 2015 | 1.41x | CN¥279.60 Million | CN¥198.13 Million | CN¥204.60 Million | ▼ -64.9% |
| 2014 | 4.02x | CN¥290.65 Million | CN¥72.24 Million | CN¥290.65 Million | ▲ +272.2% |
| 2013 | 1.08x | CN¥313.11 Million | CN¥289.62 Million | CN¥313.11 Million | ▲ +20.8% |
| 2012 | 0.89x | CN¥224.35 Million | CN¥250.72 Million | CN¥224.35 Million | ▼ -27.4% |
| 2011 | 1.23x | CN¥165.94 Million | CN¥134.58 Million | CN¥165.94 Million | ▲ +230.1% |
| 2010 | 0.37x | CN¥69.69 Million | CN¥186.55 Million | CN¥69.69 Million | ▲ +316.4% |
| 2009 | 0.09x | CN¥17.60 Million | CN¥196.14 Million | CN¥17.60 Million | ▼ -82.5% |
| 2008 | 0.51x | CN¥64.86 Million | CN¥126.59 Million | CN¥64.86 Million | ▲ +543.9% |
| 2007 | 0.08x | CN¥13.92 Million | CN¥174.94 Million | CN¥13.92 Million | — |